Breaking barriers in Triple Negative Breast Cancer (TNBC) – Unleashing the power of antibody-drug conjugates (ADCs)

Triple-negative breast cancer (TNBC) is defined by the lack of expression of estrogen receptor (ER), progesterone receptor (PgR), and human epidermal growth factor receptor 2 (HER2) on tumor cells. It accounts for 15-20% of newly diagnosed breast cancer (BC) cases and is distinguished by the least favorable prognosis among BC subtypes, along with a long-standing paucity of effective therapeutic options.[1,2] In the past few years, research breakthroughs have brought to light the significance of the TNBC microenvironment heterogeneity, revealing a dynamic relationship with cancer cell features and emphasizing the need for a more comprehensive view of TNBC as an ecosystem.

Source: Cancer Treatment Reviews - December 14, 2023 Category: Cancer & Oncology Authors: Arianna Dri, Grazia Arpino, Giampaolo Bianchini, Giuseppe Curigliano, Romano Danesi, Michelino De Laurentiis, Lucia Del Mastro, Alessandra Fabi, Daniele Generali, Alessandra Gennari, Valentina Guarneri, Daniele Santini, Edda Simoncini, Claudio Zamagni, Fa Tags: New Drugs Source Type: research